Education
About Us
Working with TipRanks
Follow Us
Takeda Pharmaceutical Co Ltd (JP:4502)
:4502
RESEARCH TOOLSreports
Total Valuation
Takeda Pharmaceutical Co has a market cap or net worth of $6.76T. The enterprise value is ¥11.18T.
Market Cap$6.76T
Enterprise Value¥11.18T
Share Statistics
Takeda Pharmaceutical Co has 1,590,962,600 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,590,962,600
Owned by Insiders0.05%
Owned by Institutions<0.01%
Financial Efficiency
Takeda Pharmaceutical Co’s return on equity (ROE) is 0.02 and return on invested capital (ROIC) is 2.67%.
Return on Equity (ROE)0.02
Return on Assets (ROA)<0.01
Return on Invested Capital (ROIC)2.67%
Return on Capital Employed (ROCE)0.04
Revenue Per Employee92.97M
Profits Per Employee2.19M
Employee Count49,281
Asset Turnover0.32
Inventory Turnover1.83
Valuation Ratios
The current PE Ratio of Takeda Pharmaceutical Co is 48.9. Takeda Pharmaceutical Co’s PEG ratio is -2.51.
PE Ratio48.9
PS Ratio1.52
PB Ratio1.00
Price to Fair Value1.00
Price to FCF9.15
Price to Operating Cash Flow6.15
PEG Ratio-2.51
Income Statement
In the last 12 months, Takeda Pharmaceutical Co had revenue of 4.58T and earned 107.93B in profits. Earnings per share was 68.36.
Revenue4.58T
Gross Profit2.36T
Operating Income523.11B
Pretax Income179.07B
Net Income107.93B
EBITDA1.15T
Earnings Per Share (EPS)68.36
Cash Flow
In the last 12 months, operating cash flow was 1.07T and capital expenditures -218.42B, giving a free cash flow of 831.40B billion.
Operating Cash Flow1.07T
Free Cash Flow831.40B
Free Cash Flow per Share522.58
Dividends & Yields
Takeda Pharmaceutical Co pays an annual dividend of ¥100, resulting in a dividend yield of 4.6%
Dividend Per Share¥100
Dividend Yield4.6%
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.51
52-Week Price Change8.16%
50-Day Moving Average4.33K
200-Day Moving Average4.20K
Relative Strength Index (RSI)46.28
Average Volume (3m)4.22M
Important Dates
Takeda Pharmaceutical Co upcoming earnings date is Oct 30, 2025, Before Open (Confirmed).
Last Earnings DateJul 30, 2025
Next Earnings DateOct 30, 2025
Ex-Dividend DateSep 29, 2025
Financial Position
Takeda Pharmaceutical Co as a current ratio of 1.01, with Debt / Equity ratio of 65.63%
Current Ratio1.01
Quick Ratio0.52
Debt to Market Cap0.65
Net Debt to EBITDA3.59
Interest Coverage Ratio2.49
Taxes
In the past 12 months, Takeda Pharmaceutical Co has paid 66.94B in taxes.
Income Tax66.94B
Effective Tax Rate0.37
Enterprise Valuation
Takeda Pharmaceutical Co EV to EBITDA ratio is 9.65, with an EV/FCF ratio of 14.57.
EV to Sales2.42
EV to EBITDA9.65
EV to Free Cash Flow14.57
EV to Operating Cash Flow11.53
Balance Sheet
Takeda Pharmaceutical Co has $419.18B in cash and marketable securities with $4.51T in debt, giving a net cash position of $4.09T billion.
Cash & Marketable Securities$419.18B
Total Debt$4.51T
Net Cash$4.09T
Net Cash Per Share$2.57K
Tangible Book Value Per Share-$1.28K
Margins
Gross margin is 60.54%, with operating margin of 11.42%, and net profit margin of 2.36%.
Gross Margin60.54%
Operating Margin11.42%
Pretax Margin3.91%
Net Profit Margin2.36%
EBITDA Margin25.11%
EBIT Margin8.49%
Analyst Forecast
The average price target for Takeda Pharmaceutical Co is $4,979.38, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$4,979.38
Price Target Upside16.75% Upside
Analyst ConsensusModerate Buy
Analyst Count4
Revenue Growth Forecast1.52%
EPS Growth Forecast-8.68%